Raleigh Capital Management’s AstraZeneca AZN Stock Holding History

Raleigh Capital Management’s Portfolio AZN Stock Details AZN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$34.9K	Sell	184 -11	-6%	-$2.07K	0.01%	305
2026 Q1	$38.5K	Buy	+195	New	+$37.6K	0.01%	304
2025 Q1	–	Sell	-389	Closed	-$51K	–	614
2024 Q4	$51K	Sell	389 -11	-3%	-$1.54K	0.02%	315
2024 Q3	$62.3K	Sell	400 -6	-1%	-$969	0.02%	303
2024 Q2	$63.3K	Buy	406 +8	+2%	+$1.2K	0.03%	280
2024 Q1	$53.9K	Sell	398 -7	-2%	-$927	0.02%	288
2023 Q4	$54.5K	Hold	405	–	–	0.03%	278
2023 Q3	$54.8K	Buy	405 +15	+4%	+$2.05K	0.03%	245
2023 Q2	$55.8K	Hold	390	–	–	0.03%	233
2023 Q1	$54.1K	Buy	390 +5	+1%	+$673	0.03%	241
2022 Q4	$52.2K	Hold	385	–	–	0.03%	238
2022 Q3	$42K	Buy	385 +3	+0.8%	+$381	0.02%	243
2022 Q2	$50K	Buy	382 +27	+8%	+$3.54K	0.03%	248
2022 Q1	$47K	Buy	+355	New	+$42.6K	0.03%	252

Other funds holding AZN

Evelyn Partners London $46.9B AUM

Investor AB Stockholm, Sweden $14.4B AUM 4.07% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Legal & General Group London, United Kingdom $480B AUM 42.84% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Raleigh Capital Management's AZN Position: Q2 2026 in Review

Raleigh Capital Management reduced its AstraZeneca (AZN) stake by 5.6% in Q2 2026, selling an estimated $2.07K and leaving 184 shares worth $34.9K. The position accounts for 0.01% of the portfolio, ranked #305.

Raleigh Capital Management first reported a position in AZN in Q1 2022 and has held it in 14 quarters since. The position peaked at $63.3K in Q2 2024. 1,507 funds tracked by Wall St. Rank hold AZN as of Q2 2026.

Raleigh Capital Management held 184 shares of AstraZeneca worth $34.9K as of Q2 2026.
Raleigh Capital Management sold 11 AstraZeneca shares in Q2 2026, an estimated $2.07K.
AstraZeneca made up 0.01% of Raleigh Capital Management's portfolio in Q2 2026, its #305 holding.
Raleigh Capital Management first reported a position in AstraZeneca in Q1 2022 and has held it in 14 quarters since.
Raleigh Capital Management's AstraZeneca position peaked at $63.3K in Q2 2024.
1,507 funds tracked by Wall St. Rank held AstraZeneca as of Q2 2026.

Based on Raleigh Capital Management's 13F filing for Q2 2026, filed 21 Jul 2026.